Caribou Biosciences, Inc. Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Noncontrolling Interest
Caribou Biosciences, Inc. (CRBU) reported Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Noncontrolling Interest of -$492.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest · last filed 2022-08-09
- Caribou Biosciences, Inc. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$492.00K.
- Caribou Biosciences, Inc. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$954.00K.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Noncontrolling Interest 6 month |
|---|---|---|
| 2022-06-30 | -$492.00K 10-Q · filed 2022-08-09 | -$1.45M derived: sum of 2 quarters · filed 2022-08-09 |
| 2022-03-31 | -$954.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |